Neural progenitors derived from human embryonic stem cells are targeted by allogeneic T and natural killer cells

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 9 B, 2009, Pages 3556-3569

  Preynat Seauve, Olivier ^a,b   de Rham, Casimir ^a   Tirefort, Diderik ^a,b   Ferrari Lacraz, Sylvie ^a   Krause, Karl Heinz ^a,b   Villard, Jean ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Cellular transplantation; Immunosuppressive drugs; Natural killer cells; Neurodegenerative diseases; Rejection mechanisms; T lymphocytes

Indexed keywords

CYCLOSPORIN; DEXAMETHASONE; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT;

ALLOTRANSPLANTATION; ARTICLE; CELL DIFFERENTIATION; CELL TRANSPLANTATION; CENTRAL NERVOUS SYSTEM; CYTOLOGY; DEGENERATIVE DISEASE; EMBRYONIC STEM CELL; FLUORESCENCE MICROSCOPY; HUMAN; METABOLISM; METHODOLOGY; NATURAL KILLER CELL; NERVE CELL; PATHOLOGY; T LYMPHOCYTE;

CELL DIFFERENTIATION; CELL TRANSPLANTATION; CENTRAL NERVOUS SYSTEM; CYCLOSPORINE; DEXAMETHASONE; EMBRYONIC STEM CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; MICROSCOPY, FLUORESCENCE; NEURODEGENERATIVE DISEASES; NEURONS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 67650377709     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00746.x     Document Type: Article

References (44)

1. Morizane A, Li JY, Brundin P. From bench to bed: the potential of stem cells for the treatment of Parkinson's disease. Cell Tissue Res. 2008, 331:323-36.
2. Grinnemo KH, Kumagai-Braesch M, Mansson-Broberg A. Human embryonic stem cells are immunogenic in allogeneic and xenogeneic settings. Reprod Biomed Online. 2006, 13:712-24.
3. Drukker M, Katz G, Urbach A. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci USA. 2002, 99:9864-9.
4. Odeberg J, Piao JH, Samuelsson EB. Low immunogenicity of in vitro-expanded human neural cells despite high MHC expression. J Neuroimmunol. 2005, 161:1-11.
5. Li L, Baroja ML, Majumdar A. Human embryonic stem cells possess immune-privileged properties. Stem Cells. 2004, 22:448-56.
6. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005, 23:225-274.
7. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol. 2005, 5:201-214.
8. Bashirova AA, Martin MP, McVicar DW. The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu Rev Genomics Hum Genet. 2006, 7:277-300.
9. Drukker M. Immunogenicity of embryonic stem cells and their progeny. Methods Enzymol. 2006, 420:391-409.
10. Spencer DD, Robbins RJ, Naftolin F. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med. 1992, 327:1541-48.
11. Winkler C, Kirik D, Bjorklund A. Cell transplantation in Parkinson's disease: how can we make it work. Trends Neurosci. 2005, 28:86-92.
12. Preynat-Seauve O, Suter DM, Tirefort D. Development of human nervous tissue upon differentiation of embryonic stem cells in three dimensional culture. Stem Cells. 2009, 27:509-20.
13. Kraus AB, Shaffer J, Toh HC. Early host CD8 T-cell recovery and sensitized anti-donor interleukin-2-producing and cytotoxic T-cell responses associated with marrow graft rejection following nonmyeloablative allogeneic bone marrow transplantation. Exp Hematol. 2003, 31:609-21.
14. Uhrberg M. The CD107 mobilization assay: viable isolation and immunotherapeutic potential of tumor-cytolytic NK cells. Leukemia 2005, 19:707-9.
15. Kaufman DB, Shapiro R, Lucey MR. Immunosuppression: practice and trends. Am J Transplant. 2004, 4:38-53.
16. Barbari AG, Masri MA, Stephan AG. Cyclosporine lymphocyte maximum level: a new alternative for cyclosporine monitoring in kidney transplantation. Exp Clin Transplant. 2005, 3:293-300.
17. Donato R, Miljan EA, Hines SJ. Differential development of neuronal physiological responsiveness in two human neural stem cell lines. BMC Neurosci. 2007, 8:36.
18. Hoffrogge R, Mikkat S, Scharf C. 2-DE proteome analysis of a proliferating and differentiating human neuronal stem cell line (ReNcell VM). Proteomics. 2006, 6:1833-47.
19. Newman MB, Bakay RA. Therapeutic potentials of human embryonic stem cells in Parkinson's disease. Neurotherapeutics. 2008, 5:237-51.
20. Jaenisch R, Young R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell. 2008, 132:567-582.
21. Rogers NJ, Lechler RI. Allorecognition. Am J Transplant. 2001, 1:97-102.
22. Villard J. Immunity after organ transplantation. Swiss Med Wkly. 2006, 136:71-7.
23. Ruggeri L, Capanni M, Urbani E. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002, 295:2097-100.
24. Ruggeri L, Mancusi A, Capanni M. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007, 110:433-40.
25. Vilches C, Parham P. Do NK-cell receptors and alloreactivity affect solid organ transplantation. Transpl Immunol. 2006, 17:27-30.
26. Moretta A, Bottino C, Vitale M. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001, 19:197-223.
27. Moretta L, Bottino C, Pende D. Human natural killer cells: molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunol Lett. 2005, 100:7-13.
28. Dressel R, Schindehutte J, Kuhlmann T. The tumorigenicity of mouse embryonic stem cells and in vitro differentiated neuronal cells is controlled by the recipients' immune response. PLoS ONE. 2008, 3:e2622.
29. Simpson E. A historical perspective on immunological privilege. Immunol Rev. 2006, 213:12-22.
30. Mason DW, Charlton HM, Jones AJ. The fate of allogeneic and xenogeneic neuronal tissue transplanted into the third ventricle of rodents. Neuroscience. 1986, 19:685-94.
31. Widner H, Brundin P. Immunological aspects of grafting in the mammalian central nervous system. A review and speculative synthesis. Brain Res. 1988, 472:287-324.
32. Moynihan JA, Santiago FM. Brain behavior and immunity: twenty years of T cells. Brain Behav Immun. 2007, 21:872-80.
33. Segal BM. The role of natural killer cells in curbing neuroinflammation. J Neuroimmunol. 2007, 191:2-7.
34. Olanow CW, Goetz CG, Kordower JH. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003, 54:403-14.
35. Freed CR, Greene PE, Breeze RE. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001, 344:710-9.
36. Chiossone L, Vitale C, Cottalasso F. Molecular analysis of the methylprednisolone-mediated inhibition of NK-cell function: evidence for different susceptibility of IL-2- versus IL-15-activated NK cells. Blood. 2007, 109:3767-75.
37. Wang H, Grzywacz B, Sukovich D. The unexpected effect of cyclosporin A on CD56+. Blood 2007, 110:1530-9.
38. Wai LE, Fujiki M, Takeda S. Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. Transplantation. 2008, 85:145-9.
39. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med. 2005, 353:1711-23.
40. Liu J, Farmer JD, Lane WS. Calcineurin is a common target of cyclophillin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991, 66:807-15.
41. Nahreini P, Hovland AR, Kumar B. Effects of altered cyclophilin A expression on growth and differentiation of human and mouse neuronal cells. Cell Mol Neurobiol. 2001, 21:65-79.
42. Chiu R, Rey O, Zheng JQ. Effects of altered expression and localization of cyclophilin A on differentiation of p19 embryonic carcinoma cells. Cell Mol Neurobiol. 2003, 23:929-43.
43. Suter DM, Krause KH. Neural commitment of embryonic stem cells: molecules, pathways and potential for cell therapy. J Pathol. 2008, 215:355-68.
44. Irons H, Lind JG, Wakade CG. Intracerebral xenotransplantation of GFP mouse bone marrow stromal cells in intact and stroke rat brain: graft survival and immunologic response. Cell Transplant. 2004, 13:283-94.